載入中
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
前收盤價
US$35.44
+US$1.23 · +3.60%
盤中時間採用ET。市場資料可能有所延遲。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日內區間
目前US$35.44
52週區間
目前US$35.44
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
4
估值過高
情緒
59
多空交錯
風險
27
中等風險
動能
71
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日內區間
目前US$35.44
52週區間
目前US$35.44
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 826萬 USD | 2905.3萬 USD | 3271.3萬 USD | 3153萬 USD | 5528.6萬 USD |
| 銷貨成本 | 128.5萬 USD | 91.1萬 USD | 159.9萬 USD | 303.4萬 USD | 896.6萬 USD |
| 毛利 | 697.5萬 USD | 2814.2萬 USD | 3111.4萬 USD | 2849.6萬 USD | 4632萬 USD |
| 研究與開發 | 6.82億 USD | 5.5億 USD | 4.4億 USD | 4.54億 USD | 4.83億 USD |
| 銷售、一般及管理費用 | 6.1億 USD | 5.91億 USD | 4.16億 USD | 3.83億 USD | 7.75億 USD |
| 營業費用 | 12.92億 USD | 11.42億 USD | 8.56億 USD | 8.38億 USD | 12.58億 USD |
| 利息收入 | 1.78億 USD | 2.58億 USD | 1.46億 USD | 3218.4萬 USD | 36.9萬 USD |
| 利息支出 | — | — | 3477.8萬 USD | 2796.8萬 USD | 704.1萬 USD |
| 折舊和攤銷 | 334.8萬 USD | 1407.1萬 USD | 2203.6萬 USD | 1885.7萬 USD | 593.2萬 USD |
| 營業利益 | −12.85億 USD | −11.14億 USD | −8.25億 USD | −8.09億 USD | −12.12億 USD |
| 淨利 | −3億 USD | −1.72億 USD | 43.49億 USD | −10.09億 USD | −8.45億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$46.75
上漲空間 31.91%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5.55億0.02%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB4.01億0.21%1853億 USD0.03%US$289.48+0.64%
Invesco S&P MidCap Momentum ETFXMMO2.46億3.45%71.38億 USD0.34%US$148.79+0.96%
Vanguard Morningstar Small-Cap Growth ETFVBK2.3億0.50%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1.81億0.19%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB1.39億1.32%108.2億 USD0.44%US$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.39億0.54%258.17億 USD0.23%US$669.87+0.54%
State Street SPDR S&P Biotech ETFXBI1.23億1.24%98.74億 USD0.35%US$153.77+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Momentum ETFXMMOVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYState Street SPDR S&P Biotech ETFXBIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
